Emergent BioSolutions (EBS) Proxy filing summary

Voting matters and shareholder proposals

• Election of four Class II directors for terms expiring at the 2029 Annual Meeting, with nominees Sujata Dayal, John Fowler, Jr., Zsolt Harsanyi, Ph.D., and Joseph Papa recommended for election.

• Ratification of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.

• Advisory vote to approve 2025 compensation for named executive officers.

• Approval sought for an amendment to the Amended and Restated Stock Incentive Plan to increase the number of shares available for awards.

• Provision to transact other business as may properly come before the meeting or any adjournment.

Board of directors and corporate governance

• Board recommends voting in favor of all director nominees and all proposals presented.

• Director terms for those elected will expire at the 2029 Annual Meeting.

Executive compensation and say-on-pay

• Advisory vote scheduled to approve 2025 compensation for named executive officers.

• Proposal includes an amendment to the stock incentive plan to increase available shares for grants.